Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
Certified by Founder
Lodge
Glycomine Inc.
start up
United States
- San Carlos, California
- 17/04/2025
- Series C
- $115,000,000
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- Industry Biotechnology Research
- Website https://www.glycomine.com/
- LinkedIn https://www.linkedin.com/company/glycomine-inc-/
Related People
Steven AxonFounder
United States -
Cohasset, Massachusetts
Specialties: Biotech, Business Development,
Corporate Strategy, Corporate Finance, Alliance Management
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)